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Abstract The neuronal-specific cholesterol 24S-hydroxylase
(CYP46A1) is important for brain cholesterol elimination.
Cyp46a1 null mice exhibit severe deficiencies in learning
and hippocampal long-term potentiation, suggested to be
caused by a decrease in isoprenoid intermediates of the
mevalonate pathway. Conversely, transgenic mice overex-
pressing CYP46A1 show an improved cognitive function.
These results raised the question of whether CYP46A1 ex-
pression can modulate the activity of proteins that are crucial
for neuronal function, namely of isoprenylated small guano-
sine triphosphate-binding proteins (sGTPases). Our results
show that CYP46A1 overexpression in SH-SY5Y neuroblas-
toma cells and in primary cultures of rat cortical neurons leads
to an increase in 3-hydroxy-3-methyl-glutaryl-CoA reductase
activity and to an overall increase in membrane levels of
RhoA, Rac1, Cdc42 and Rab8. This increase is accompanied
by a specific increase in RhoA activation. Interestingly, treat-
ment with lovastatin or a geranylgeranyltransferase-I inhibitor
abolished the CYP46A1 effect. The CYP46A1-mediated in-
crease in sGTPases membrane abundance was confirmed
in vivo, in membrane fractions obtained from transgenic mice
overexpressing this enzyme. Moreover, CYP46A1 overex-
pression leads to a decrease in the liver X receptor (LXR)
transcriptional activity and in the mRNA levels of ATP-
binding cassette transporter 1, sub-family A, member 1 and
apolipoprotein E. This effect was abolished by inhibition of
prenylation or by co-transfection of a RhoA dominant-
negative mutant. Our results suggest a novel regulatory axis
in neurons; under conditions of membrane cholesterol reduc-
tion by increased CYP46A1 expression, neurons increase
isoprenoid synthesis and sGTPase prenylation. This leads to
a reduction in LXR activity, and consequently to a decrease in
the expression of LXR target genes.
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Introduction
Cholesterol, apart from being an essential component of cel-
lular membranes, is a key regulator of cellular processes in the
central nervous system (CNS), playing a role in promoting
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neurite outgrowth [1–5], in synaptogenesis and synaptic in-
tegrity, and in neurotransmitter release [6–9]. In addition to the
brain-specific activities, cholesterol synthesis generates inter-
mediate products, such as isoprenoids and ubiquinone [10].
Therefore, constant levels of this sterol are required for normal
brain functioning. Its homeostasis is maintained, in part, by an
efficient blood–brain barrier that prevents exchanges with
lipoprotein cholesterol from circulation. Thus to meet choles-
terol needs, de novo and in situ synthesis occur in the CNS.
The conversion of cholesterol into 24(S)-hydroxycholesterol
(24OHC), by the neuronal-specific cytochrome P450 choles-
terol 24S-hydroxylase (CYP46A1), has been described as the
major cholesterol elimination mechanism [11–13]. In vitro,
24OHC has been shown to be a ligand for the liver X receptor
(LXR) [14, 15]. Surprisingly, however, in transgenic mice
overexpressing CYP46A1, activation of the LXR pathway
was not observed, despite the higher levels of 24OHC [16].
In accordance to this, selective overexpression of CYP46A1,
in the cortex and hippocampus of transgenic mice model for
AD, ameliorated the amyloid β pathology, without activation
of the LXR pathway [17]. Knockout mice lacking Cyp46a1
have a≈40 % reduction in brain cholesterol excretion, but this
decrease is compensated for by a reduction in the de novo
synthesis that maintains normal steady-state levels [13].
Cyp46a1 null mice exhibit severe deficiencies in spatial,
associative and motor learning, and hippocampal long-term
potentiation (LTP) [18, 19]. Interestingly, these studies with
knockout mice are consistent with the possibility that a de-
crease in cholesterol synthesis may limit the supply of iso-
prenoid intermediates of the mevalonate pathway, required for
learning and synaptic plasticity. Accordingly, transgenic mice
overexpressing CYP46A1 exhibit increased brain cholesterol
synthesis, increased levels of synaptic proteins in the hippo-
campus, as well as improved memory function when com-
pared to wild-type controls [16, 20].
These results have raised the question of whether
CYP46A1 expression levels may alter the availability of
isoprenoids intermediates, possibly affecting the amount of
crucial isoprenylated proteins in neurons. Indeed, mevalonate,
the product of 3-hydroxy-3-methyl-glutaryl-CoA reductase
(HMGR), can be converted into farnesyl-diphosphate (FFP)
and geranylgeranyl-diphosphate (GGPP) that, among other
functions, can covalently bind to proteins, such as most small
guanosine triphosphate-binding proteins (sGTPases), and act
as anchors for membrane association. sGTPases comprise a
superfamily of monomeric proteins classified into, at least,
five families (Ras, Rho, Rab, Sar1/Arf, and Ran) that are
involved in complex signaling networks and regulate diverse
cellular activities. These activities include intracellular vesicle
transport, cell adhesion, endocytosis, cytoskeletal organiza-
tion, cell cycle progression, receptor signaling, vesicle traf-
ficking, and gene expression [21, 22]. Membrane association
and targeting, binding to regulators, and activation of
downstream effectors are dependent on lipid post-
translational modifications for all sGTPases, except those
from the Ran family [21]. Sar/Arf sGTPases undergo post-
translational myristoylation, while the Ras, Rho, and Rab
families undergo a C-terminal prenylation.While Ras proteins
are farnesylated [23, 24], Rho proteins are geranylgeranylated
or farnesylated [25], and Rab proteins are mainly di-
g e r a n y l g e r a n y l a t e d b u t s ome c a n b e mon o -
geranylgeranylated [26, 27]. Prenylated sGTPases cycle be-
tween a GDP (inactive)/GTP (active) binding conformation
that combines with cytosol/membrane alternation, which is
mediated by guanine dissociation inhibitors. These latter in-
hibitors form soluble complexes with sGTPases by binding
their lipid moiety and are responsible for the extraction and
delivery of sGTPases to membranes [21, 28].
Rho proteins have been extensively associated with actin
cytoskeleton remodeling and are therefore critical to CNS
neuronal cell migration, axon growth, guidance and
branching, dendritic spine formation and stabilization, growth
cone motility and collapse, and synapse formation [29–31].
Additionally, Rho GTPases have also been implicated in the
correct formation of myelin sheaths [32]. Ras are involved in
axon growth, memory formation, LTP induction and mainte-
nance, and synaptic modulation [31, 33, 34], while Rab pro-
teins have been mainly associated with endocytosis, synaptic
vesicles exocytosis, axonal retrograde transport, and postsyn-
aptic compartment dynamics of glutamate receptors [35]. In
accordance to their pivotal role in the CNS, Ras, Rho, and Rab
sGTPases have also been implicated in a number of neurolog-
ical diseases. These diseases range from genetic defects such
as X-linked non-specific mental retardation, Niemann–Pick
disease Type C or choroideremia to sporadic neurological
disorders such as late-onset AD, Parkinson’s disease, multiple
sclerosis, brain tumors, or even brain disorders resulting from
ischemic stroke [10, 30, 36–42].
In the present work, evidence is presented that CYP46A1
expression levels are able to modulate isoprenoids synthesis
and, ultimately, protein prenylation and activation of
sGTPases. This modulation is shown to be important for
activation of the LXR signaling system. Our results explain
the surprising finding that this system is not activated in
CYP46A1 transgenic mice in spite of high levels of the
efficient LXR activator 24S-hydroxycholesterol [16].
Materials and Methods
Reagents and Antibodies
The following primary antibodies were used: anti-RhoA
(clone 67B9, #2177; Cell Signaling Technology, Beverly,
MA, USA), anti-Rac1 (clone 23A8, #05-389; Millipore, Te-
mecula, CA, USA), anti-Rab8 (clone 4/Rab4, #610844; BD
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Transduction Laboratories), anti-Cdc42 (clone B-8, sc-8401;
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-
apolipoprotein E (APOE) (clone M-293, sc-98574; Santa
Cruz), anti-glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (clone 6C5, sc-32233; Santa Cruz), anti-
FLAG®M2 (clone M2, F1804; Sigma-Aldrich Inc., St Louis,
MO, USA), anti-calnexin (ab7580; Abcam, Cambridge, UK),
and anti-HA-Peroxidase (3F10) (#12013819001, Roche Ap-
plied Science). The chemical inhibitors GGTi-2133 and lova-
statin were purchased from Sigma and Pefabloc® fromRoche.
Cell Culture
The SH-SY5Y human neuroblastoma cell line was cultured as
previously described [43]. Briefly, cells were maintained in
low glucose DMEM (Sigma), at 37 °C in humidified 5 %
CO2. The media was supplemented with 10% heat inactivated
fetal bovine serum, 2 mML-glutamine, 100 units/mL penicil-
lin, and 100 μg/mL streptomycin (Gibco®, Invitrogen).
Primary cultures of rat cortical neurons were prepared from
17- to 18-day-old fetuses of Wistar rats as described previous-
ly [44] with minor modifications. In short, pregnant rats were
sacrificed in a CO2 chamber and the fetuses were collected in
Hank’s balanced salt solution and rapidly decapitated. After
removal of meninges and white matter, the brain cortex was
collected in Hank’s balanced salt solution without Ca2+ and
Mg2+ (HBSS-2). The cortex was then mechanically
fragmented, transferred to 0.05 % trypsin, and incubated for
15 min at 37 °C. Following trypsinization, cells were washed
twice in HBSS-2 containing 10 % fetal bovine serum and
resuspended in Neurobasal medium (Gibco®), supplemented
with 0.5 mML-glutamine, 25 μM L-glutamic acid, 2 % B-27
supplement (Gibco®), and 12 mg/mL gentamicin. Isolated
neurons were plated with a density around 640/mm2 on culture
plates pre-coated with poly-D-lysine and maintained at 37 °C in
a humidified atmosphere of 5 % CO2. Half of the medium of
the neuronal primary cultures was changed every 3–4 days until
the 26th day in vitro (26DIV). Glutamic acid was only added
into the medium when plating the cells. All the media changes
and cell treatments afterwards were free from glutamic acid.
Preparation of Cytosolic and Membrane Fractions and Total
Extracts from Cultured Cells
For the isolation of cytosolic and membrane fractions, cells
were harvested in ice-cold cell wash buffer (10 mMTris–HCl,
pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol
[DTT], and 1 mM of Pefabloc®), and centrifuged at 1,000×g
for 10 min at 4 °C. The pellet was resuspended in cell homog-
enisation buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA,
0.25 M sucrose, 1 mM DTT, 1× protease inhibitor cocktail-
Roche Diagnostics GmbH, Penzberg, Germany) and homog-
enized by 20 passages through a 23× gauge needle attached to
a 1-mL syringe. The homogenate was centrifuged at 10,000×g
for 5 min and the post-nuclear supernatant obtained was
subjected to ultra-centrifugation at 100,000×g for 1 h at
4 °C. The supernatant (cytosolic fraction—S100) was collect-
ed and the pellet (membrane fraction—P100) was resuspend-
ed in homogenization buffer.
For the preparation of total cell extracts, cells were harvest-
ed in phosphate-buffered saline and resuspended in lysis
buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 %
Triton-X 100) containing 1 mM DTT and 1× protease inhib-
itor mixture. After incubation at 4 °C, for 30 min, samples
were sonicated four times for 4 s each, on ice, followed by
centrifugation at 12,000×g for 15 min at 4 °C.
Protein concentration was determined by Bradford method
and extracts were stored at −80 °C until further use.
Preparation of Cytosolic and Membrane Fractions from Mice
Brain Cortex
Brain cortex tissue was obtained from wild-type and homozy-
gous HA-tagged CYP46A1 transgenic mice, previously de-
scribed and characterized [20]. Heterozygous mice cross-bred
with C57Bl6 mice [16] from the sixth generation were inbred
for an additional three generations in order to obtain the
homozygous mice [20]. To isolate the cytosolic and mem-
brane fractions of brain cortex tissue, a slice was cut and
placed in ice-cold tissue homogenization buffer (250 mM
Sucrose, 100 mM potassium phosphate pH 6.7, 5 mMMgCl2,
1 mMDTT, and 1× protease inhibitor mixture). The tissuewas
homogenized with a motor-driven Bio-vortexer (NO1083;
Biospec Products, Bartlesville, OK, USA) and centrifuged at
3,500×g for 10 min at 4 °C. The resulting pellet, containing
nuclei and cell debris, was discarded and the supernatant was
further centrifuged at 100,000×g for 30 min at 4 °C. The
supernatant (cytosolic fraction—S100) was collected and the
pellet (membrane fraction—P100) was resuspended in ho-
mogenization buffer.
Western Blot Analysis
Proteins were subject to SDS-PAGE gels, electroblotted onto
Immobilon P membrane (IPVH00010, Millipore), and incu-
bated with specific antibodies. Results were quantified using
the Quantity One version densitometry analysis software
(Bio-Rad Laboratories Inc., Hercules, CA, USA).
RhoA Activity Assay
RhoA activity was measured in SH-SY5Y cells lysates using
an ELISA-based RhoA activation assay Biochem Kit™ (G-
LISA™, Cytoskeleton Inc., Denver, CO, USA), according to
the manufacturer’s instructions. Briefly, fresh cell lysates were
added to the RhoA-GTP affinity plate that was coated with the
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Rhotekin-binding domain of RhoA for 30 min. The lysates
were incubated with primary and secondary antibodies for
45 min each. After adding the detection reagent, the lumines-
cence was measured in GloMax®-Multi Detection System
(Promega, Madison, WI, USA).
Expression Analysis
Total cell RNA was extracted using Trizol Reagent
(Invitrogen) following manufacturer’s instructions. Real-time
PCR (qPCR) analysis for HMGR and 3-hydroxy-3-methyl-
glutaryl-coenzyme A synthase (HMGS), LDL receptor
(LDLR), ATP-binding cassette transporter, sub-family A,
member 1 (ABCA1), and APOE was performed using SYBR
green Master Mix in an ABI 7300 sequence detection system
(Applied Biosystems, Foster City, CA, USA) and specific
primers (Table 1). Results presented were obtained from at
least three individual experiments and each sample was
assayed in triplicate. The mRNA levels of the genes of interest
were normalized to themRNA levels ofβ-actin and expressed
as fold changes relative to controls, using the ΔΔCt method.
Statistical analysis was performed with the ΔCt values.
HMG-CoA Reductase Activity Levels
HMGR activity was measured using the HMG-CoA Reduc-
tase Assay Kit (Sigma) following manufacturer’s instructions.
Briefly, the cells were harvested and subjected to a centrifu-
gation of 500×g, 5 min at 4 °C. The pellet was resuspended in
1× assay buffer and homogenized by 20 passages through a
25× gauge needle attached to a 2-mL syringe. The cell extract
was centrifuged again for 5 min, 500×g at 4 °C and the
supernatant containing the cellular content was collected.
After protein content determination by the Bradford method,
150 μg of cell extract were added to a reaction solution
containing 400 μM NADPH, 0.3 mg/mL HMGCR with or
without 500 nM pravastatin in a total volume of 200 μL per
well in a 96-well plate. The absorbance at 340 nm was
subsequently measured every 30 s for 50 min in Infinite®
M200 (Tecan, Männedorf, Switzerland). The decrease in ab-
sorbance represents the oxidation of NADPH mediated by
HMGR. Each sample was assayed in duplicate. The results
are expressed as nanomole of NADPH consumed per minute
per milligram of protein.
Gene Reporter Assay
To minimize variations in transfection efficiency, replicates
were transfected in single batch suspension with X-
tremeGENE HP (Roche), according to the manufacturer’s
instructions. Plates containing 150,000 cells were co-
transfected with 0.5 μg of the reporter plasmid, 0.1 μg of each
expression vector, together with 0.025 μg of aβ-galactosidase
expression plasmid (pSV40-βGAL). Cells were inoculated in
24-well plates and maintained for 48 h. Cells were harvested
and lysed in reporter lysis buffer (Promega). Cell extracts were
assayed for luciferase and β-galactosidase activity (β-Gal
Reporter Gene Assay, Roche).
Total Cholesterol Levels
Total cholesterol was quantified using the Amplex® Red
cholesterol assay kit (Invitrogen) according to the manufac-
turer’s instructions. Cell membrane fractions were diluted
1:50 in 1× reaction buffer and 50 μL was used to quantify
cholesterol. Samples were placed in a 96-well plate and the
reaction was initiated by adding 50 μL of the Amplex® Red
reagent/HRP/cholesterol oxidase/cholesterol esterase working
solution to each well. The reactions were incubated for 30 min
at 37 °C. Fluorescence measurements were performed in a
GloMax®-Multi Detection System (Promega). Each sample
was assayed in triplicate. Cholesterol levels were normalized
with total protein levels and expressed as microgram of cho-
lesterol per milligram of protein.
Statistics
Statistical analysis was performed using the Student’s t test,
Mann–Whitney test, the ANOVA one-way and ANOVA two-
way tests followed by Tukey or Dunnet multiple comparisons
test. All analysis was performed using the GraphPad Prism
Table 1 List of primers used for qPCR
Gene Species Sequence (5′ – 3′) / source
HMGR Human 5′ ATAGGAGGCTACAACGCCCAT 3′ (fwd)
5′ TTCTGTGCTGCATCCTGTCC 3′(rev)
HMGS Human 5′ GGCACAGCTGCTGTCTTCAAT 3′ (fwd)
5′ ACCAGGGCATACCGTCCAT 3′ (rev)
LDLR Human 5′ CAGATATCATCAACGAAGC 3′ (fwd)
5′ CCTCTCACACCAGTTCACTCC 3′ (rev)
APOE Human 5′ GACTGGCCAATCACAGGC 3′ (fwd)
5′ CTGTCTCCACCGCTTGCTC 3′ (rev)
Rat 5′ CTTCTGGATTACCTGCGCT 3′ (fwd)
5′ GTCCTCCATCAGTACCGTCAG 3′ (rev)
ABCA1 Human 5′ CCTGTTTCCGTTACCCGACTC 3′ (fwd)
5′ ACAGGCGAGCCACAATGG 3′ (rev)
Rat 5′ CCCGGCGGAGTAGAAAGG 3′ (fwd)
5′ AGGGCGATGCAAACAAAGAC 3′ (rev)
β – actin Human 5′ CTGGAACGGTGAAGGTGACA 3′ (fwd)
5′ AAGGGACTTCCTGTAACAATCCA 3′ (rev)
Rat 5′ CTTGCAGCTCCTCCGTCGCC 3′ (fwd)
5′ CTTGCTCTGGGCCTCGTCGC 3′ (rev)
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version 5.01 for Windows, GraphPad Software, La Jolla,
California, USA, www.graphpad.com.
Results
Overexpression of CYP46A1 Increases sGTPases Prenylation
and Activity
We have hypothesized that alterations in CYP46A1 expres-
sion levels may affect the availability of isoprenoid interme-
diates of the mevalonate pathway, thereby influencing the
amount of crucial isoprenylated proteins in neuronal cells.
Although it has been described that a decrease in cholesterol
synthesis affects the supply of isoprenoids inCyp46a1 knock-
out mice [18, 19], it is not known whether this decrease
influences protein prenylation, which is a critical post-
translational modification for many signalling proteins, name-
ly most sGTPases. Therefore, we started to investigate wheth-
er an increase in CYP46A1 expression affects prenylation and
activity of members of the Rho and Rab families of sGTPases
in two different cellular models, with distinct endogenous
CYP46A1 expression levels. We have used primary cultures
of rat cortical neurons maintained for 26DIV which express
high levels of CYP46A1, and SH-SY5Y human neuroblasto-
ma cells, where CYP46A1 mRNA can barely be detected
[43].
Firstly, to determine if the recombinant CYP46A1 protein
retains its catalytic activity, we have transfected SH-SY5Y
cells and 26DIV neurons with an expression vector coding for
the human CYP46A1 (pFLAG-hCYP46A1) for 48 and 24 h,
respectively. These time points were chosen based on a time
course analysis of transient CYP46A1 protein expression
levels (data not shown). As expected, CYP46A1 overexpres-
sion induced a significant decrease in membrane cholesterol
content. Membrane cholesterol levels decrease by 60 % in
SH-SY5Y cells and by 30 % in 26DIV neurons transfected
with pFLAG-hCYP46A1 as compared to cells transfected
with empty vector (pFLAG) (Fig. 1).
Prenylation is an essential modification for membrane an-
choring of sGTPases. Hence, membrane association of
sGTPases provides a sensitive measure of their prenylation
status [23]. Therefore, we have isolated membrane and cyto-
solic fractions of SH-SY5Y cells and 26DIV neurons, and the
content of RhoA, Rac1, Cdc42, and Rab8 was determined by
immunoblotting.
Our results show an overall significant increase in mem-
brane association of all sGTPases tested after CYP46A1 over-
expression in SH-SY5Y cells and 26DIV neurons (Fig. 2). In
fact, we observed an increase of about 35, 53, 63, and 130 %
in the membrane levels of RhoA, Rac1, Cdc42, and Rab 8,
respectively, in SH-SY5Y cells transfected for 48 h with
pFLAG-hCYP46A1, as compared to cells transfected with
empty vector (Fig. 2a). Concomitantly, we could observe a
significant decrease of about 50, 30, 25, and 20 % in the
cytosolic levels of RhoA, Rac1, Cdc42, and Rab 8, respec-
tively (Fig. 2b). These results were further confirmed in
26DIV neurons transfected with pFLAG-hCYP46A1 for
24 h, where we could also observe a significant increase of
approximately 65, 26, 21, and 97% in the membrane levels of
RhoA, Rac1, Cdc42, and Rab 8, respectively (Fig. 2c) and a
concomitant decrease of about 5 % in RhoA and Rac1, and 15
and 25 % in Cdc42 and Rab8, respectively in the cytosolic
fraction (Fig. 2d). Importantly, this CYP46A1-dependent in-
crease of membrane-associated sGTPases is not due to an
increase in their abundance as the analysis of total cell protein
extracts by immunoblotting shows that the total protein levels
of the tested sGTPases remain unchanged after overexpres-
sion of hCYP46A1 both in neuroblastoma cells and in 26DIV
neurons (data not shown).
Overall, these results clearly demonstrate the effective
translocation of RhoA, Rac1, Cdc42, and Rab8 from the
cytosol to membranes induced by increased CYP46A1
expression.
To assess if the CYP46A1-dependent increase in the mem-
brane association of sGTPases is dependent on the cellular
isoprenoid pool, we treated cells with lovastatin, an inhibitor
of HMGR, the enzyme responsible for the rate-limiting step
for cholesterol and isoprenoid production. Since lovastatin
affects membrane association of sGTPases of both Rho and
Rab families, and once we had observed a higher increase in
Rab8 membrane content, we have chosen to determine the
effect of lovastatin treatment in the CYP46A1-dependent
increase in membrane association of this sGTPase. SH-
SY5Y cells were transfected with pFLAG-hCYP46A1 or with
empty vector and, 24 h afterwards, were treated with vehicle
0
100
200
300
400
Empty hCYP
M
em
b
ra
n
e 
ch
o
le
st
er
o
l l
ev
el
(µ
g
 / 
m
g
 p
ro
te
in
)
0
50
100
150
Empty hCYP
M
em
b
ra
n
e 
ch
o
le
st
er
o
l l
ev
el
(µ
g
 / 
m
g
 p
ro
te
in
)
NeuronsSH-SY5Y
**
**
Fig. 1 CYP46A1 overexpression reduces cholesterol content in the
membrane fraction of SH-SY5Yand 26DIV neurons. Membrane choles-
terol levels were determined with the Amplex®Red cholesterol determi-
nation kit in the membrane fraction isolated from SH-SY5Y cells and in
26DIV neurons transfected with empty pFLAG (Empty) or pFLAG-
hCYP46A1 (hCYP) for 48 and 24 h, respectively. Data represents mean
values±SEM from at least three independent experiments and is
expressed as microgram of membrane cholesterol per milligram of mem-
brane protein (**p<0.01)
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or with 20 μM lovastatin for another 24 h. Not only lovastatin
treatment decreased the amount of membrane-associated
Rab8 by 60 % in cells transfected with the empty vector but,
more interestingly, it completely abolished the increase in
Rab8 membrane content induced by CYP46A1 overexpres-
sion (two-way ANOVA p<0.001, Tukey HSD post hoc test)
(Fig. 3).
To further confirm that the increase in CYP46A1 expres-
sion correlates with an increase in protein prenylation, we also
determined the effect of geranygeranyl transferase inhibition
on the CYP46A1-dependent sGTPase membrane association.
GGTase-I recognizes protein substrates that have a consensus
sequence termed “CAAX box” located at the carboxy termi-
nus, and therefore target proteins of the Rho family. In con-
t ras t , p ro te ins of the Rab fami ly undergo two
geranylgeranylation reactions and are almost exclusively the
substrates for GGTase-II. Nevertheless, it has been shown that
some members of the Rab family, such as Rab8, can also be
prenylated by GGTase-I [27, 26]. Therefore, we transfected
SH-SY5Y cells with pFLAG-hCYP46A1 or with empty vec-
tor and after 24 h cells were treated with either vehicle or
50 nM GGTi-2133, a GGTase-I inhibitor, for further 24 h.
Finally, the effect on the membrane content of one of the
members of the Rho family, RhoA, and on Rab8 was analyzed
by immunoblotting. Our results show that GGTi-2133 treat-
ment, as expected, slightly decreases RhoA (15 %), but not
Rab8 basal membrane association, while it clearly inhibits the
CYP46A1-dependent increase in RhoA (two-way ANOVA
p<0.001; Tukey HSD post hoc) and Rab8 (two-way ANOVA
p<0.001; Tukey HSD post hoc test) (Fig. 4).
These results highlight that compounds that either decrease
the cellular isoprenoid pool or inhibit geranylgeranylation
reactions abolish the increased membrane association of
sGTPases upon CYP46A1 overexpression, indicating that
the observed differences are due to sGTPase prenylation.
Moreover, we also wanted to evaluate if this increase in
sGTPases prenylation was reflected in an increased activation.
Therefore, we used a G-LISA kit assay to evaluate RhoA
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Fig. 2 CYP46A1 overexpression in human SH-SY5Y cells and 26DIV
neurons increases sGTPases membrane association.Western blot analysis
of sGTPases content in membrane (a and c) and cytosolic (b and d)
fractions, 48 and 24 h after transfection of SH-SY5Y cells and 26DIV
neurons, respectively, with empty pFLAG (Empty) or with pFLAG-
hCYP46A1 (hCYP). GAPDH and calnexin levels were used as loading
control for cytosolic and membrane fractions, respectively. The blots
shown are representative of those obtain in at least three independent
experiments. Data is represented as mean values±SEM of at least three
experiments and is expressed as fold change relative to control (*p<0.05,
**p<0.01, ***p<0.001)
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activity in cell extracts from SH-SY5Y transfected for 24 h
with pFLAG-hCYP46A1 or with empty vector and treated
with vehicle or 50 nM GGTi-2133 for further 24 h after
transfection. Our results show that CYP46A1 significantly
increases GTP-bound RhoA by approximately 50 %, which
reflects an increase in RhoA activation status. GGTi-2133
treatment completely abrogates the CYP46A1 effect (two-
way ANOVA p<0.05, Tukey HSD post hoc test) (Fig. 5).
Since CYP46A1 effect seems to be dependent on the
supply of isoprenoids, we decided to assess how CYP46A1
overexpression affects the mevalonate pathway, by measuring
HMGR activity 48 h after transfection of SH-SY5Y with
pFLAG-hCYP46A1 or with empty vector (Fig. 6). The addi-
tion of 500 μM pravastatin to non-transfected SH-SY5Y cell
homogenates resulted in a 70 % reduction of the basal
NADPH consumption, while in the homogenates of cells that
were serum starved for 24 h, the NADPH consumption dou-
bled when compared to control (0.47±0.18 nmol NADPH/
min/mg protein) (ANOVA p<0.001, F=16.62, Tukey HSD
post hoc test) (Fig. 6a). These data suggested that the NADPH
consumption in these homogenates was specifically due to
HMGR activity. Interestingly, overexpression of CYP46A1
induces a 2.3-fold significant increase in the rate of NADPH
oxidation that is abolished by pravastatin addition, further
confirming that this effect is due to an increase in HMGR
activity (ANOVA p<0.05, F=5.305, Tukey HSD post hoc
test) (Fig. 6b).
These results are in agreement with the significant increase
in the levels of several cholesterol precursors that were previ-
ously described in the brains of transgenic mice overexpress-
ing HA-CYP46A1 (C46-HA mice) [16]. To further confirm
our observations, we isolatedmembrane and cytosolic fraction
from the brain cortex of C46-HA mice and determined by
immunoblotting the content of RhoA, Rac1, Cdc42, and Rab8
in both fractions. We observed an increase in membrane
association of RhoA, Rac1, and Rab8 in C46-HA mice rela-
tive to wt controls that was similar to what was shown in
cultured cells (Fig. 7). The membrane-associated level of
RhoA, Rac1, and Rab8 increased by approximately 48, 89,
and 18 %, respectively, and this was accompanied by a con-
comitant decrease in the abundance of sGTPases in the cytosol
by 37, 34, and 44 % relative to wt controls. However, in the
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case of Cdc42, there was a reduction of approximately 50% in
both membrane and cytosolic fractions, which indicates a
reduction of Cdc42 expression in these mice. When the values
of membrane-associated Cdc42 are normalized to the total
pool of membrane and cytosolic Cdc42, there is no statistical
significant change between transgenic and wild-type mice
(data not shown).
All together, these results show that CYP46A1 overexpres-
sion activates the mevalonate pathway and increases
sGTPases prenylation and activation.
24(S)-Hydroxycholesterol, in Contrast to CYP46A1
Overexpression, Reduces RhoA Membrane Association
24OHC is the endogenous product of cholesterol oxidation
mediated by CYP46A1, therefore to assess if the observed
changes in sGTPases induced by CYP46A1 overexpression
were due to an increased production of this oxysterol, 26DIV
neurons were incubated with 10 μM 24OHC for 24 h. Since,
in vitro, 24OHC activates LXR, in parallel experiments we
incubated cells with 10 μM TO901317, an LXR synthetic
agonist. Total extracts and membrane fractions were obtained
as previously described and the sGTPases content was
assessed by Western blot. We observed that both 24OHC
and TO901317 had similar effects, but neither recapitulated
the overall increase in membrane-associated sGTPases in-
duced by overexpression of CYP46A1. Indeed, although both
LXR agonists induced a significant 40 to 50 % increase of
Rac1, Rab8, and Cdc42 content in the membrane fraction
(Fig. 8), RhoA content in the membrane fraction was reduced
by about 35 and 20 % with 24OHC and TO901317, respec-
tively (one-way ANOVA p<0.001, F=18.97; p<0.01, F=
17.37; p<0.01, F=8.316; and p<0.01, F=10.78, correspond-
ing to RhoA, Rac1, Cdc42, and Rab8 analysis, respectively,
Dunnet post hoc test) (Fig. 8). These results indicate that
CYP46A1 overexpression and 24OHC have similar effects
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for Rac1, Cdc42, and Rab8 but opposite roles concerning
RhoA membrane association.
CYP46A1 Overexpression Inhibits the LXR Pathway as
a Consequence of RhoA Activation
As previously mentioned, inactivation of Cyp46a1 has been
associated with a selective reduction of cholesterol synthesis
[13], while a significant increase in the levels of several
cholesterol precursors was observed in the brain of CYP46A1
transgenic mice [16, 20]. Moreover, herein we have also
observed an increase in HMGR activity in CYP46A1
transfected cells. Taken together, these findings suggest a
close relationship between synthesis and catabolism of cho-
lesterol in the brain. Therefore, we have determined by qPCR
the mRNA levels of key genes involved in cholesterol ho-
meostasis, namely HMGS and HMGR (synthesis), LDLR
(uptake), ABCA1, and APOE (efflux) in SH-SY5Y cells
transfected with hCYP46A1. Although we had previously
observed an increase in HMGR activity, our results show that
HMGS and HMGR mRNA levels remain unchanged after
CYP46A1 overexpression (Fig. 9a) which is consistent with
the gene expression profile reported for C46-HA mice [20].
On the other hand, the mRNA levels of the LXR target genes,
ABCA1 and APOE, were significantly down-regulated by
approximately 30 and 20 %, respectively. To further confirm
the CYP46A1 effect, we also transfected N26DIV neurons
with pFLAG-hCYP46A1 and observed similar reductions of
ABCA1 and APOE mRNA levels about 15 and 20 %, respec-
tively (Fig. 9b). Furthermore, this decrease is not underlined
by a reduction in LXRα and LXRβ expression, since their
mRNA levels remain unchanged after CYP46A1 overexpres-
sion (data not shown). It was initially hypothesized that an
increase in CYP46A1 expression would lead to increased
levels of 24OHC and to a general activation of LXR and
LXR-targeted genes in the brain. However, the observed
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Fig. 7 Brain cortex of C46-HA mice present an increase in sGTPases
membrane association. Western blot analysis of sGTPases content in
membrane and cytosolic fractions (a–d) of C46-HA mice brain cortex.
GAPDH and calnexin levels were used as loading control for cytosolic
and membrane fractions, respectively. Data is represented as mean values
±SEM and is expressed as arbitrary units (*p<0.05, **p<0.01,
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down-regulation of ABCA1 and APOE after CYP46A1 over-
expression did not corroborate this hypothesis. Moreover,
recent results from Shaffati and collaborators [16], obtained
with the transgenic C46-HA mice, also showed that higher
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Fig. 8 24OHC and TO901317
affect sGTPases membrane
association in 26DIV neurons.
Western blot analysis of
sGTPases content in the
membrane fraction of 26DIV
neurons incubated with 10 μM
24OHC or TO901317 for 24 h.
Values were normalized to the
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represented as mean values±
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mRNA levels. a qPCR analysis of
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levels 24OHC due to CYP46A1 overexpression were not
sufficient to drive LXR activation in vivo.
In order to compare the effect of CYP46A1 overexpression
with 24OHC treatment, we have treated 26DIV neurons with
24OHC and determined the mRNA levels of LXR target
genes. Our results show that incubation of 10 μM 24OHC
increases ABCA1 and APOE mRNA levels by five and
twofold, respectively, which is the opposite effect of
CYP46A1 overexpression (one-way ANOVA p<0.001, F=
8.536; p<0.05, F=5.577 for ABCA1 andAPOE, respectively,
Dunnet post hoc test) (Fig. 10).
Since activation of Rho GTPases has been associated with
an inhibition of the LXR pathway [45–49] and we have
observed that CYP46A1 overexpression and 24OHC treat-
ment differentially affect RhoA membrane levels, we hypoth-
esize that CYP46A1-dependent decrease in LXR target genes
was dependent on the increase in RhoA prenylation. To test
our hypothesis, we incubated cells transfected with pFLAG-
hCYP46A1 in the presence or absence of GGTi-2133 and
observed that inhibition of prenylation abolished the
CYP46A1-dependent decrease in ABCA1 and APOE mRNA
levels (Fig. 11a). Moreover, we observed that co-transfection
of a dominant-negative form of RhoA (pEGFP-RhoA N19)
also leads to the loss of the CYP46A1 effect (Fig. 11b). To
further confirm that CYP46A1 overexpression affects LXR
activation, we performed a reporter gene assay in SH-SY5Y
cells co-transfected with the luciferase reporter plasmids
LXRE-ABCA1 or LXREmut-ABCA1 and with empty vector
or pFLAG-hCYP46A1 for 48 h (Fig. 12). Upon CYP46A1
overexpression, we observed a 40 % decrease in luciferase
activity in cells transfected with the LXRE-ABCA1 luciferase
reporter plasmid, an effect that was not observed in cells
transfected with the LXRE mut-ABCA1 luciferase reporter
plasmid (Fig. 12a). In addition, we have co-transfected the
pEGFP-RhoA N19 or the pEGFP empty vector with the
luciferase reporter plasmids, and we observed that the
CYP46A1-dependent decrease in LXR transcriptional activity
was rescued by the inhibition of RhoA activity (Fig. 12b).
These results indicate that overexpression of CYP46A1
can effectively activate sGTPases signaling cascades and have
a downstream impact in neuronal cells, namely the down-
regulation of the LXR pathway mediated by RhoA.
Discussion
The present work identifies CYP46A1 as a major player in the
regulation of prenylation and activity of sGTPases in neuronal
cells. We show that CYP46A1 overexpression induces the
activation of the mevalonate pathway, and thereby increases
the pool of isoprenoids, as reflected by an increase in
prenylation and activation of sGTPases. These results suggest
that modulation of CYP46A1 expression can alter the content of
prenylated proteins and their activity in neuronal cells, namely
that of sGTPases. As mentioned above, these proteins are
involved in several CNS pivotal processes ranging from endo-
cytosis to synapticmodulation. Interestingly,Cyp46a1 null mice
have decreased cognitive functions [18, 19] and, in contrast,
transgenic mice overexpressing CYP46A1 possess an improve-
ment of cognitive functions [20]. In both cases, these effects
were suggested to be due to the inactivation or activation of the
mevalonate pathway, respectively. Interestingly, the LTP defi-
ciencies in the knockout mice lacking Cyp46a1 could not be
restored by addition of cholesterol [18] which suggests that
cholesterol levels are not directly implicated in cognitive chang-
es elicited by modulation of CYP46A1 expression. In light of
these studies and the present results, we put forward the hypoth-
esis that CYP46A1 can influence high-order brain functions
such as memory and learning, in part, through modulation of
prenylation and activation status of sGTPases. This mechanism
may also be part of the explanation for the cognitive improve-
ment in the AD mice model overexpressing CYP46A1 [17].
Indeed, as above-mentioned sGTPases proteins are involved in
the control axon growth, guidance and branching, dendritic
spine formation and stabilization, growth cone motility and
collapse and synapse formation [29–31], and consequently on
memory formation, LTP induction and maintenance, and syn-
aptic modulation [31, 33, 34]. We are currently investigation the
full impact of CYP46A1-dependent sGTPases activation, name-
ly in terms of neuronal development and function.
Interestingly, in contrast to the effect of CYP46A1 overex-
pression, incubation with 24OHC decreases membrane associ-
ation of RhoA, while it increases the membrane abundance of
the other sGTPases studied. LXR ligands have been previously
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shown to have differential effects on the activation of Rho
family members, namely by inhibiting RhoA and activating
Cdc42 [50, 51]. Moreover, RhoA has been reported to inhibit
LXR [45–49], suggesting integration between Rho-dependent
functions and LXR activation. Our experiments on the effect of
CYP46A1 overexpression on the LXR pathway show that, in
contrast to the effect of added 24OHC, increased levels of
CYP46A1 reduced the expression of LXR target genes ABCA1
and APOE, which are critical for cholesterol efflux in neurons
[52–56]. Interestingly, this decrease was abolished in the pres-
ence of a prenyltransferase inhibitor or by the co-transfection of
a RhoA dominant-negative mutant. In agreement with the
CYP46A1-dependent decrease in ABCA1 and APOE mRNA
levels, we observed that the increase in CYP46A1 expression
negatively affected the LXR transcriptional activity, and that this
decrease was once again rescued by co-transfection of a RhoA
dominant-negative mutant. These results strongly indicate that
CYP46A1 overexpression can repress the LXR pathway in
neurons through the activation of RhoA, in a prenylation-
dependent manner. It is tempting to suggest that the present data
reflect a global mechanism of cellular response to cholesterol
reduction by CYP46A1 in neurons. In order to avoid cholesterol
depletion, the cells activate cholesterol synthesis in parallel with
a down-regulation of the LXR target genes related to cholesterol
efflux (ABCA1 and ApoE). Acute cholesterol depletion by
cyclodextrin treatment results in altered membrane properties
that can affect synaptic transmission in Purkinje cells and wild-
type hippocampal neurons [57, 58]. On the other hand, Sodero
and coworkers have suggested that a sudden rise in excitatory
neurotransmission activate CYP46A1-dependent mild choles-
terol loss mechanisms to protect themselves from neuronal
death [59]. Since CYP46A1 activity produces 24OHC, one
may speculate that the CYP46A1–sGTPases–LXR axis in
neurons is an additional layer of the cell’s cholesterol qual-
ity control, impairing cholesterol reduction to levels that
may affect synaptic transmission. Interestingly, our results
may also explain the previous in vivo reports that overex-
pression of CYP46A1 in mice does not lead to activation of
the LXR pathway in spite of the high levels of the efficient
LXR agonist 24OHC [16, 17].
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